Saturday 17 October 2026 Export BPTSY’s income statement to Excel — free account

Biophytis SA Sponsored ADR

BPTSY Healthcare Biotechnology

Operating cash flow growth for three consecutive years.

0.25 0.00 0.00%

Follow BPTSY

Alert me

Market cap: $2.4M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 99.02%

Capital & Financial Ratios $m

Market Cap 2.36

Revenue —

Net Income (39.86)

Free Cash Flow (33.89)

Net Debt 7.15

Current Ratio 0.35

Debt/Equity (0.99)

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 47.40%

Next Y EPS Growth 0.00%

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2022	2023	2024	Q'25
Cash	12	6	0	2
Receivables	7	3	4	3
Inventory	—	—	—	—
Other	—	—	—	—
	20	10	4	4

	2022	2023	2024	Q'25
Payables	7	6	5	5
ST’ Debt	11	5	10	5
Other	0	1	1	1
	20	13	17	12

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	—	—	—	(9)
’23	—	—	—	—	(14)
’22	—	—	—	—	(20)
’21	—	—	—	—	(28)
’20	—	0	—	—	(11)
’19	—	(12)	—	(6)	(18)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(4)	—	—	—
’24	—	(6)	—	(9)	(9)
’23	—	(9)	—	(14)	(14)
’22	—	(11)	—	(20)	(20)
’21	—	(16)	—	(28)	(29)
’20	—	0	—	(11)	(12)
’19	—	(12)	—	(6)	(18)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	—	—	—	(216.42)
’23	—	—	—	—	(135.60)
’22	—	—	—	—	(590.00)
’21	—	—	—	—	(1.23k)
’20	—	(0.28)	—	—	(1.28k)
’19	—	(0.86)	—	(0.36)	(1.18)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	—	—	—	—	—	1,860.00	140.00	20.00	2.82	Analyst estimates 2025–2027 Powerpack
	High	—	—	—	—	—	—	7,400.00	2,364.00	360.80	27.20
People
People	Employees	—	—	—	—	—	23	25	25	24	19
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	EBT	—	(10)	(17)	(20)	(23)	(19)	(37)	(26)	(18)	(11)
	EBT margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	(8)	0	(16)	(20)	(19)	(37)	(26)	(18)	(11)
	Depreciation	—	0	0	0	0	5	1	1	1	1
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	(1.35)	(1.49)	(1.21)	(1.18)	(1,280.00)	(1,232.00)	(590.00)	(135.60)	(216.42)
	Cash flow	—	(8.42)	(6.63)	(36.96)	(36.63)	(751.18)	(951.08)	(457.80)	(102.60)	(180.20)
	Capex	—	0.00	0.00	0.00	0.00	(16.30)	(13.75)	(3.40)	(1.75)	0.21
	Free cash flow	—	(8.42)	(6.63)	(36.96)	(36.63)	(767.48)	(964.83)	(461.20)	(104.35)	(180.00)
	Book value	—	5.79	16.13	20.23	(16.89)	520.28	228.03	(46.07)	(30.99)	(202.28)
	Shares, m	—	1	2	0	1	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	(7)	(11)	(15)	(18)	(11)	(28)	(20)	(14)	(9)
	Capex	—	0	0	0	0	0	0	0	0	0
	Free cash flow	—	(7)	(11)	(15)	(18)	(12)	(29)	(20)	(14)	(9)
Balance, $m
Balance, $m	Working capital	—	3	23	13	(6)	6	10	(1)	(4)	(13)
	Total debt	—	1	0	8	16	10	22	15	9	11
	Net debt	—	(2)	(24)	(9)	9	(11)	(8)	3	3	10
	Shareholders’ equity	—	5	26	8	(8)	8	7	(2)	(4)	(10)
Returns, %
Returns, %	ROA	—	(41.76)	(311.18)	(94.81)	(89.06)	(76.56)	(99.93)	(77.24)	(102.06)	(110.04)
	ROIC	—	0.00	0.00	0.00	0.00	0.00	0.00	(1,417.57)	0.00	0.00
	ROE	—	(55.17)	(90.58)	(95.69)	9,235.28	5,835.11	(508.01)	(1,077.40)	592.38	152.74

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EIGRQ Eiger BioPharmaceuticals, Inc.	$2.6M	— (loss-making)	— (loss-making)	+41.06% (above 0%: growing)	n/m	+37.90% (above 0%: growing)	97.34%	(331.69%)	Compare
BIORQ Biora Therapeutics, Inc.	$2.5M	— (loss-making)	— (loss-making)	+1,500.00% (above 0%: growing)	n/m	+20.72% (above 0%: growing)	100.00%	(50,709.38%)	Compare
ELAB PMGC Holdings Inc.	$2.5M	— (loss-making)	—	+147.70% (above 0%: growing)	n/m	−44.95% (below 0%: shrinking)	29.52%	(292.91%)	Compare
NTBLQ Notable Labs, Ltd.	$2.4M	— (loss-making)	— (loss-making)	−96.88% (below 0%: shrinking)	n/m	−26.63% (below 0%: shrinking)	100.00%	(269,000.00%)	Compare
VBIO Valion Bio, Inc.	$2.4M	— (loss-making)	— (loss-making)	+15.87% (above 0%: growing)	n/m	−189.01% (below 0%: shrinking)	(99.32%)	0.00%	Compare
MTNB Matinas Biopharma Holdings, Inc.	$2.4M	— (loss-making)	— (loss-making)	+365,433.33% (above 0%: growing)	n/m	+9.15% (above 0%: growing)	0.00%	0.00%	Compare
BPTSY Biophytis SA Sponsored ADR	$2.4M	— (loss-making)	—	—	n/m	+53.15% (above 0%: growing)	0.00%	—
WINT Windtree Therapeutics, Inc.	$2.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	+1.12% (above 0%: growing)	0.00%	0.00%	Compare
KAPA Kairos Pharma, Ltd.	$2.3M	— (loss-making)	—	—	n/m	−25.71% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$2.4M	—	—	+41.06%	—	−12.29%	29.52%	(146.45%)

All 614 Biotechnology stocks →